Log in to search using one of your social media accounts:

 

Effects of physical exercise on breast cancer-related secondary lymphedema: a systematic review
ConclusionThe evidence indicates that exercise can improve subjective and objective parameters in BCRL patients, with dynamic, moderate, and high-frequency exercise appearing to provide the most positive effects. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 22, 2018 Category: Cancer & Oncology Source Type: research

Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations
ConclusionIn India, socioeconomic inequality limiting access to treatment is a major factor towards increased cancer burden; therefore, incorporation of a cost-effective and comprehensive multi-gene test will be helpful in ensuring widespread implementation of genetic screening in the clinical practice for hereditary breast and/or ovarian cancers. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 22, 2018 Category: Cancer & Oncology Source Type: research

Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations
ConclusionsNeoadjuvant versus adjuvant with standard anthracycline- and taxane-containing regimens results in similar disease-free survival and overall survival among patients with stage I and II triple-negative breast cancer regardless of BRCA status. Further studies are needed to evaluate whether similar results are observed with newer agents. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 22, 2018 Category: Cancer & Oncology Source Type: research

Characterization of a novel breast cancer cell line derived from a metastatic bone lesion of a breast cancer patient
ConclusionThis novel human breast cancer-bone metastasis cell line will be a useful model to study aspects of breast cancer biology, particularly metastasis-related changes from breast to bone. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 21, 2018 Category: Cancer & Oncology Source Type: research

Tumor-associated macrophages and crown-like structures in adipose tissue in breast cancer
AbstractPurposeWe aimed to evaluate macrophage infiltration and to identify the status of crown-like structures (CLSs) in mammary adipose tissue of human breast tissue in cases with and without breast cancer.MethodsBreast adipose tissue was obtained from reduction mammoplasty (N = 56, Group 1), non-neoplastic breast tissue of breast cancer patients (N = 84, Group 2), and breast cancer with adipose stroma (N = 140, Group 3). Immunohistochemical staining of CD68 and CD163 was performed, and the infiltrating macrophages and CLSs within breast adipose tissue were evaluated.ResultsGroup 3 had the l...
Source: Breast Cancer Research and Treatment - February 21, 2018 Category: Cancer & Oncology Source Type: research

Long-term survival and cure model following liver resection for breast cancer metastases
AbstractIntroductionLong-term survival is still rarely achieved with current systemic treatment in patients with breast cancer liver metastases (BCLM). Extended survival after hepatectomy was examined in a select group of BCLM patients.Patients and methodsHepatectomy for BCLM was performed in 139 consecutive patients between 1985 and 2012. Patients who survived  
Source: Breast Cancer Research and Treatment - February 20, 2018 Category: Cancer & Oncology Source Type: research

A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer
ConclusionWe have identified a novelGLI1 gene signature that is associated with worse clinical outcomes among the patients with Luminal A subtype of breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 20, 2018 Category: Cancer & Oncology Source Type: research

Factors associated with improved outcomes for metastatic inflammatory breast cancer patients
This study aims to determine indicators of prognosis, including primary tumor resection, for stage IV IBC patients.MethodsUsing the National Cancer Data Base, female patients diagnosed 2010 –2013 with unilateral a priori metastatic T4d invasive adenocarcinoma of the breast were identified. We conducted propensity score matched analysis to balance confounders of surgery versus no-surgery. Stratified log-rank test and double-robust estimation under the Cox model were used to assess the effect of surgery, and margins, on overall survival (OS) in the propensity score matched cohort.ResultsOf 1266 patients, 41% underwent ...
Source: Breast Cancer Research and Treatment - February 19, 2018 Category: Cancer & Oncology Source Type: research

Acute toxicity of intraoperative radiotherapy and external beam-accelerated partial breast irradiation in elderly breast cancer patients
AbstractBackground and purposeWe investigated the acute toxicity of accelerated partial breast irradiation using external beam (EB-APBI) or intraoperative radiotherapy (IORT) techniques in elderly breast cancer patients.Materials and methodsWomen  ≥ 60 years with unifocal breast tumors of ≤ 30 mm were eligible for this prospective multi-center cohort study. IORT was applied with electrons following lumpectomy (23.3 Gy). EB-APBI was delivered using 3D-CRT or IMRT in 10 daily fractions of 3.85 Gy within 6 weeks after surgery. Acut e toxicity was scored using the CTCAE v3.0 a...
Source: Breast Cancer Research and Treatment - February 19, 2018 Category: Cancer & Oncology Source Type: research

Metastasis of breast cancer prior to invasion
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 19, 2018 Category: Cancer & Oncology Source Type: research

Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03)
AbstractPurposeAromatase inhibitors are the most commonly prescribed adjuvant endocrine therapy for hormone-dependent early breast cancer in postmenopausal women. Among Canadian Cancer Trials Group MA.27 participants, anastrozole and exemestane had comparable 5-year event-free survival. This companion study examined differences in patient-reported treatment-related symptoms (TRS) and health-related quality of life (HRQL) among postmenopausal women randomized to anastrozole or exemestane.MethodsMA.27 participants (N = 686, of 7576) randomized to 5 years of anastrozole (1 mg/day,n = 371, Arm A) or ex...
Source: Breast Cancer Research and Treatment - February 17, 2018 Category: Cancer & Oncology Source Type: research

Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy
ConclusionsThis study provides a rationale for the further development of PSMA-targeted imaging in breast cancer, especially in triple-negative tumors. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 17, 2018 Category: Cancer & Oncology Source Type: research

Safety and feasibility of breast lesion localization using magnetic seeds (Magseed): a multi-centre, open-label cohort study
ConclusionsMagnetic seeds are a feasible and safe method of breast lesion localization. They can be accurately placed, demonstrate no migration in this feasibility study and are detectable in all sizes and depths of breast tissue. Now that safety and feasibility have been demonstrated, further clinical studies are required to evaluate the seed ’s effectiveness in wide local excision surgery. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 16, 2018 Category: Cancer & Oncology Source Type: research

Lipid-lowering drugs, dyslipidemia, and breast cancer risk in a Medicare population
AbstractPurposeWe sought to disentangle the effects of statins and other lipid-lowering drugs and the underlying dyslipidemia for which they are prescribed on breast cancer risk.MethodsWe conducted a case –control study within the linked Surveillance, Epidemiology, and End results (SEER)-Medicare data. Cases were women with invasive breast cancer aged 66 + years (N = 30,004) identified by SEER registries (years 2007–2011). Controls were women (N = 198,969) identified from a 5% random sample of Medicare recipients alive and breast cancer free in year of selection. Participants had a...
Source: Breast Cancer Research and Treatment - February 15, 2018 Category: Cancer & Oncology Source Type: research

A comparison of two models for breast cancer mortality for women with ductal carcinoma in situ: an SEER-based analysis
ConclusionsIn the SEER database, we observed far more deaths from DCIS than would be expected under a model where all deaths from breast cancer occur amongst women who experience an invasive local recurrence. This lends support to the hypothesis that DCIS mortality is not restricted to those women who experience an in-breast invasive cancer and that DCIS has properties similar to small invasive breast cancers. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 14, 2018 Category: Cancer & Oncology Source Type: research

Differences in breast cancer incidence among young women aged 20 –49 years by stage and tumor characteristics, age, race, and ethnicity, 2004–2013
In this study, we examined recent trends and variations in breast cancer incidence among young women in the United States.MethodsUsing 2004 –2013 National Program of Cancer Registries and Surveillance, Epidemiology, and End Results Program data, we calculated breast cancer incidence rates and trends and examined variations in stage, grade, and tumor subtype by age and race/ethnicity among young women aged 20–49 years.ResultsThe majority of breast cancer cases occurred in women aged 40 –44 and 45–49 years (77.3%). Among women aged 
Source: Breast Cancer Research and Treatment - February 14, 2018 Category: Cancer & Oncology Source Type: research

Evaluation of [ 89 Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer
Conclusions[89Zr]trastuzumab has the potential to characterize the HER2 status of the complete tumor burden in patients with breast cancer, thus obviating repeat or multiple tissue sampling to assess intrapatient heterogeneity of HER2 status. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 13, 2018 Category: Cancer & Oncology Source Type: research

The clinical impact of molecular breast imaging in women with proven invasive breast cancer scheduled for breast-conserving surgery
ConclusionMBI seems to be a useful imaging modality with a high predictive value in revealing ipsilateral and bilateral disease not visualized by mammography and ultrasound. It may play an important role in delineating the extent of the index lesion during preoperative planning. Incorporation of MBI in the clinical work-up as an adjunct modality to mammography and ultrasound may lead to better selection of patients who could benefit from BCS. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 13, 2018 Category: Cancer & Oncology Source Type: research

Do patients whose tumor achieved a pathological response relapse at specific sites? A substudy of the EORTC 10994/BIG-1-00 trial
ConclusionPatients that achieved a pCR appeared less likely to present with skeletal metastases and more frequently presented with CNS metastases as first site of distant relapse, even after adjustment for molecular subtypes. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 12, 2018 Category: Cancer & Oncology Source Type: research

Chest wall recurrence in pT1-2N0-1 breast cancer patients after mastectomy without radiotherapy
ConclusionsThe incidence of CWR in pT1-2N0-1 breast cancer patients is very low, especially with isolated recurrence. Also, the obtained data showed that the nodal status had no impact on CWRFS. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 12, 2018 Category: Cancer & Oncology Source Type: research

Is invasion a necessary step for metastases in breast cancer? Narod SA, Sopik V
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 12, 2018 Category: Cancer & Oncology Source Type: research

Performance of breast cancer screening using digital breast tomosynthesis: results from the prospective population-based Oslo Tomosynthesis Screening Trial
This study investigated the effects of addition of DBT on interval and detected cancers in population-based screening.MethodsOslo Tomosynthesis Screening Trial (OTST) was a prospective, independent double-reading trial inviting women 50 –69 years biennially, comparing full-field digital mammography (FFDM) plus DBT with FFDM alone. Performance indicators and characteristics of screen-detected and interval cancers were compared with two previous FFDM rounds.Results24,301 consenting women underwent FFDM  + DBT screening over a 2-year period. Results were compared with 59,877 FFDM examinations during prior...
Source: Breast Cancer Research and Treatment - February 10, 2018 Category: Cancer & Oncology Source Type: research

MOBCdb: a comprehensive database integrating multi-omics data on breast cancer for precision medicine
Conclusion In summary, MOBCdb provides users a unique web interface to the integrated multi-omics data of different subtypes of breast cancer, which enables the users to identify potential novel biomarkers for precision medicine. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 10, 2018 Category: Cancer & Oncology Source Type: research

Breast cancer subtype and survival by parity and time since last birth
AbstractBackgroundPregnancy affects breast cancer risk but how it affects the subtype and prognosis remain controversial. We studied the effect of parity and time since last birth on breast cancer subtype and outcome.Patients and methodsWe conducted a retrospective multivariate cohort study including all premenopausal women with early breast cancer aged  ≤ 50 years (N = 1306) at diagnosis at the University Hospitals Leuven (Jan. 2000–Dec. 2009). Primary study endpoints were the breast cancer subtype, disease-free survival, and distant disease-free survival by parity and time since last bir...
Source: Breast Cancer Research and Treatment - February 10, 2018 Category: Cancer & Oncology Source Type: research

Association between financial burden and adjuvant hormonal therapy adherence and persistent use for privately insured women aged 18 –64 years in BCBS of Texas
ConclusionsFinancial burdens including both non-AHT medication and AHT-specific out-of-pocket costs were significantly associated with adherence and persistence to the therapy. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 8, 2018 Category: Cancer & Oncology Source Type: research

Impact of physiological hormonal fluctuations on 18 F-fluorodeoxyglucose uptake in breast cancer
ConclusionsOur data suggest that18F-FDG uptake may be impacted by physiological hormonal fluctuations during menstrual cycle in luminal A-like cancers, and that E2 could be partly responsible for these events. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 8, 2018 Category: Cancer & Oncology Source Type: research

Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis
AbstractPurposeResults from clinical trials of adjuvant dose-dense chemotherapy in patients with breast cancer are inconsistent.MethodsA systematic search of MEDLINE identified studies comparing the efficacy of dose-dense adjuvant chemotherapy to a standard treatment. The primary analysis included studies that used identical regimens in the experimental and control groups, but varied only dose density. A secondary analysis included studies that used either different drugs or doses in the experimental and the control groups. Hazard ratios (HRs) and 95% confidence intervals were computed for disease-free survival (DFS) and o...
Source: Breast Cancer Research and Treatment - February 8, 2018 Category: Cancer & Oncology Source Type: research

First international TNBC conference meeting report
This report distills the burning questions that spi ked the event and summarizes key themes, findings, unique opportunities and future directions that emerged from this confluence of thought leaders. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 8, 2018 Category: Cancer & Oncology Source Type: research

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review
ConclusionsThe development of drugs targeting the PI3K/AKT/mTOR pathway for the treatment of TNBC is an evolving field that should take into account the efficacies and toxicities of new agents in addition to their interactions with different cancer pathways. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 7, 2018 Category: Cancer & Oncology Source Type: research

Cell growth inhibition and apoptosis in breast cancer cells induced by anti-FZD7 scFvs: involvement of bioinformatics-based design of novel epitopes
ConclusionsBioinformatic methods could effectively select potential epitopes of FZD7 protein and suggest that epitope designing by bioinformatic methods could contribute to the selection of key antigens for cancer immunotherapy. The selected scFvs, especially scFv-I, with high antiproliferative and apoptotic effects could be considered as effective agents for immunotherapy of cancers expressing FZD7 receptor including triple negative breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 6, 2018 Category: Cancer & Oncology Source Type: research

Reply to K. Altundag
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 6, 2018 Category: Cancer & Oncology Source Type: research

Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
ConclusionsThese findings suggest that early-life physical activity is associated with a reduced risk of premenopausal breast cancer amongBRCA mutation carriers.ImpactFuture prospective analyses, complemented by mechanistic evidence, are warranted in this high-risk population. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 5, 2018 Category: Cancer & Oncology Source Type: research

First-line ribociclib plus letrozole in postmenopausal women with HR+  , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial
ConclusionRIB plus LET versus PBO plus LET is associated with earlier and more durable tumor response, greater degree of tumor shrinkage and pain reduction, and PFS benefit irrespective of TFI. These data further support RIB plus LET as a first-line treatment option for postmenopausal women with HR+  , HER2− ABC. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 5, 2018 Category: Cancer & Oncology Source Type: research

Complications following immediate compared to delayed deep inferior epigastric artery perforator flap breast reconstructions
ConclusionsThis study demonstrated similar incidences of major recipient-site complications and flap re-explorations between immediate and delayed DIEP flap breast reconstructions. However, hematoma and seroma occurred significantly more often in immediate reconstructions, while wound problems were more frequently observed in delayed reconstructions. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 5, 2018 Category: Cancer & Oncology Source Type: research

Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy
AbstractPurposePhosphate and tensin homolog (PTEN), a negative regulator of PI3K signaling, is involved in DNA repair. ATR is a key sensor of DNA damage and replication stress. We evaluated whether ATR signaling has clinical significance and could be targeted by synthetic lethality in PTEN-deficient triple-negative breast cancer (TNBC).MethodsPTEN, ATR and pCHK1Ser345 protein level was evaluated in 1650 human breast cancers. ATR blockade by VE-821 was investigated in PTEN-proficient- (MDA-MB-231) and PTEN-deficient (BT-549, MDA-MB-468) TNBC cell lines. Functional studies included DNA repair expression profiling, MTS cell-p...
Source: Breast Cancer Research and Treatment - February 2, 2018 Category: Cancer & Oncology Source Type: research

Rapid review: radiomics and breast cancer
ConclusionsThe study of radiomics in BC patients is a new and emerging translational research topic. Radiomics in BC is frequently done to potentially improve diagnosis and characterization, mostly using MRI. Substantial quality limitations were found; high-quality prospective and reproducible studies are needed to further potential application. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 2, 2018 Category: Cancer & Oncology Source Type: research

The heterogeneity of cancer
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 2, 2018 Category: Cancer & Oncology Source Type: research

Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I –III HER2-positive breast cancer
AbstractPurposeThe purpose of this two-cohort Phase II trial was to estimate the pathologic complete response (pCR: ypT0/is ypN0) rate when trastuzumab plus pertuzumab are administered concurrently during both the taxane and anthracycline phases of paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) neoadjuvant chemotherapy.MethodsThe pCR rates were assessed separately in hormone receptor (HR) positive and negative cases following Simon ’s two-stage design, aiming to detect a 20% absolute improvement in pCR rates from 50 to 70 and 70 to 90% in the HR-positive and HR-`negative cohorts, respectively.Results...
Source: Breast Cancer Research and Treatment - February 2, 2018 Category: Cancer & Oncology Source Type: research

Cross-reactivity between MUC1 antigen and MCA: false elevation of serum CA 15-3 level in pregnant and lactating women by Ma695 –Ma552-based assay
ConclusionsThe CA 15-3 assay using 115D8 –DF3 antibody pair is more suitable for monitoring therapy in pregnancy-associated breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 2, 2018 Category: Cancer & Oncology Source Type: research

Dose adjustment in obese breast cancer patients receiving neoadjuvant chemotherapy might have an impact on survival
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 1, 2018 Category: Cancer & Oncology Source Type: research

Does the elevation of CAMLs predict metastatic breast cancer patients ’ survival?
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 1, 2018 Category: Cancer & Oncology Source Type: research

Reclassifying HER2-equivocal disease
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 1, 2018 Category: Cancer & Oncology Source Type: research

A novel patient-derived xenograft model for claudin-low triple-negative breast cancer
ConclusionsHere, we characterize a claudin-low TNBC patient-derived xenograft model that can be utilized for therapeutic research studies. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 1, 2018 Category: Cancer & Oncology Source Type: research

Systematical analysis of lncRNA –mRNA competing endogenous RNA network in breast cancer subtypes
ConclusionThis study provided a novel perspective of lncRNA-involved ceRNA network to dissect the molecular mechanism for breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 1, 2018 Category: Cancer & Oncology Source Type: research

Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience
ConclusionsIT trastuzumab was well tolerated with prolongation of OS over historical controls. IT trastuzumab should be considered for management of HER2+ leptomeningeal disease patients. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - February 1, 2018 Category: Cancer & Oncology Source Type: research

A comprehensive tool for measuring mammographic density changes over time
AbstractBackgroundMammographic density is a marker of breast cancer risk and diagnostics accuracy. Density change over time is a strong proxy for response to endocrine treatment and potentially a stronger predictor of breast cancer incidence. We developed STRATUS to analyse digital and analogue images and enable automated measurements of density changes over time.MethodRaw and processed images from the same mammogram were randomly sampled from 41,353 healthy women. Measurements from raw images (using FDA approved software iCAD) were used as templates for STRATUS to measure density on processed images through machine learni...
Source: Breast Cancer Research and Treatment - February 1, 2018 Category: Cancer & Oncology Source Type: research

A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer
ConclusionsThe prognostic staging system is a refined version of the anatomic staging system and encourages a more personalized approach to breast cancer treatment. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 31, 2018 Category: Cancer & Oncology Source Type: research

Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies
ConclusionsThe combined analysis provides refined estimates of 10-year LR risk after BCS for DCIS. Adding information on tumor size and age at diagnosis to the DS adjusting for year of diagnosis provides improved LR risk estimates to guide treatment decision making. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - January 31, 2018 Category: Cancer & Oncology Source Type: research

The frequency of missed breast cancers in women participating in a high-risk MRI screening program
AbstractPurposeTo evaluate the frequency of missed cancers on breast MRI in women participating in a high-risk screening program.MethodsPatient files from women who participated in an increased risk mammography and MRI screening program (2003 –2014) were coupled to the Dutch National Cancer Registry. For each cancer detected, we determined whether an MRI scan was available (0–24 months before cancer detection), which was reported to be negative. These negative MRI scans were in consensus re-evaluated by two dedicated breast radiolog ists, with knowledge of the cancer location. Cancers were scored as invisi...
Source: Breast Cancer Research and Treatment - January 31, 2018 Category: Cancer & Oncology Source Type: research

Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database
AbstractPurposeTo determine the prognostic role of tamoxifen therapy for patients with ductal carcinoma in situ (DCIS) according to molecular subtypes.MethodsData of 14,944 patients with DCIS were analyzed. Molecular subtypes were classified into four categories based on expression of estrogen receptor (ER)/progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). Kaplan –Meier estimator was used for overall survival analysis while Cox proportional hazards model was used for univariate and multivariate analyses.ResultsLuminal A subtype (ER/PR+, HER2 −) showed higher (P = .009) su...
Source: Breast Cancer Research and Treatment - January 30, 2018 Category: Cancer & Oncology Source Type: research